BR112022019206A2 - Tratamento de infecções por coronavírus - Google Patents

Tratamento de infecções por coronavírus

Info

Publication number
BR112022019206A2
BR112022019206A2 BR112022019206A BR112022019206A BR112022019206A2 BR 112022019206 A2 BR112022019206 A2 BR 112022019206A2 BR 112022019206 A BR112022019206 A BR 112022019206A BR 112022019206 A BR112022019206 A BR 112022019206A BR 112022019206 A2 BR112022019206 A2 BR 112022019206A2
Authority
BR
Brazil
Prior art keywords
treatment
infections
coronavirus
coronavirus infections
relates
Prior art date
Application number
BR112022019206A
Other languages
English (en)
Inventor
Bruce Lars
Original Assignee
Tx Medic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tx Medic Ab filed Critical Tx Medic Ab
Publication of BR112022019206A2 publication Critical patent/BR112022019206A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

TRATAMENTO DE INFECÇÕES POR CORONAVÍRUS. A invenção refere-se ao sulfato de dextrana, ou um sal farmaceuticamente aceitável do mesmo, para uso no tratamento de uma infecção por coronavírus ou doença infecciosa e infecções causadas por outros patógenos de ligação a HSPG. A invenção também se refere ao tratamento de doenças inflamatórias, tais como ARDS e SIRS, que podem ocorrer em conexão com tais infecções.
BR112022019206A 2020-04-15 2021-04-14 Tratamento de infecções por coronavírus BR112022019206A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063010211P 2020-04-15 2020-04-15
PCT/SE2021/050344 WO2021211043A1 (en) 2020-04-15 2021-04-14 Treatment of coronavirus infections

Publications (1)

Publication Number Publication Date
BR112022019206A2 true BR112022019206A2 (pt) 2022-11-08

Family

ID=78084830

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022020881A BR112022020881A2 (pt) 2020-04-15 2021-04-14 Tratamento da sepse e hipercitocinemia
BR112022019206A BR112022019206A2 (pt) 2020-04-15 2021-04-14 Tratamento de infecções por coronavírus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022020881A BR112022020881A2 (pt) 2020-04-15 2021-04-14 Tratamento da sepse e hipercitocinemia

Country Status (10)

Country Link
US (2) US20230346827A1 (pt)
EP (2) EP4135719A4 (pt)
JP (2) JP7788730B2 (pt)
KR (2) KR20230002698A (pt)
CN (2) CN115551520A (pt)
AU (2) AU2021255662A1 (pt)
BR (2) BR112022020881A2 (pt)
CA (2) CA3174935A1 (pt)
IL (2) IL296600A (pt)
WO (2) WO2021211043A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021211043A1 (en) * 2020-04-15 2021-10-21 Tx Medic Ab Treatment of coronavirus infections
SE544447C2 (en) * 2020-09-29 2022-05-31 Tx Medic Ab Treatment of fatty liver diseases
BR112023021145A2 (pt) * 2021-04-14 2023-12-12 Tx Medic Ab Tratamento de infecções por vírus
CN119424418A (zh) * 2024-12-06 2025-02-14 华中科技大学 Dock2抑制剂cpypp在制备抗血栓的药物中的应用
CN120405150B (zh) * 2025-07-01 2025-11-18 南昌大学第一附属医院 Itga6在制备脓毒症诊断及病情监测试剂或试剂盒中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892103A (ja) * 1994-09-22 1996-04-09 Teijin Ltd 硫酸化糖を有効成分とするホスホリパーゼａ２ 阻害剤
DE69621528T2 (de) * 1995-02-07 2003-01-16 Shiseido Co. Ltd., Tokio/Tokyo Anti-inflamatorische agenzien
JPH08277224A (ja) * 1995-02-07 1996-10-22 Shiseido Co Ltd 抗炎症剤
JP2000507204A (ja) * 1995-12-18 2000-06-13 ステイヒテイング・サンキン・ブロードボールジーニング Ｃ１―インヒビターの補体及び血液凝固阻害特性の強化
SE9904289D0 (sv) 1999-11-26 1999-11-26 Niklas Arnberg Method and camposition for the treatment of adenovairal ocular infections
US20030181416A1 (en) 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
SE525461C3 (sv) * 2002-11-28 2005-03-23 Prophymed Ab Ny användning av dextransulfat
US20050004071A1 (en) * 2003-04-21 2005-01-06 Comper Wayne D. Charged polysaccharides resistant to lysosomal degradation during kidney filtration and renal passage and their use to treat or prevent infection by coronaviruses
EP1718315A4 (en) 2004-02-06 2008-08-13 Univ Monash HIGH DOSE USE OF SULFATED POLYSACCHARIDES IN SHORT INTERVALS FOR THE TREATMENT OF INFECTIONS
CA2685208C (en) * 2007-04-24 2014-04-08 Novelmed Therapeutics, Inc. Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
JP2011020938A (ja) 2009-07-14 2011-02-03 Ini:Kk 抗インフルエンザウイルス剤
SE538503C2 (en) * 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
CA3074987A1 (en) * 2017-09-08 2019-03-14 Tx Medic Ab New use of dextran sulfate
SE544015C2 (en) * 2019-06-18 2021-11-02 Tx Medic Ab Allogenic car-t cell therapy
WO2021211043A1 (en) * 2020-04-15 2021-10-21 Tx Medic Ab Treatment of coronavirus infections

Also Published As

Publication number Publication date
WO2021211043A1 (en) 2021-10-21
KR20230002698A (ko) 2023-01-05
JP7758356B2 (ja) 2025-10-22
CN115551520A (zh) 2022-12-30
EP4135719A1 (en) 2023-02-22
EP4135719A4 (en) 2024-06-19
JP2023521916A (ja) 2023-05-25
WO2021211044A1 (en) 2021-10-21
JP2023521919A (ja) 2023-05-25
AU2021255662A1 (en) 2022-11-10
IL296600A (en) 2022-11-01
EP4135720A4 (en) 2024-04-17
EP4135720A1 (en) 2023-02-22
AU2021255044A1 (en) 2022-11-10
CN115461060A (zh) 2022-12-09
CA3174935A1 (en) 2021-10-21
KR20230004557A (ko) 2023-01-06
US20230346827A1 (en) 2023-11-02
CA3174977A1 (en) 2021-10-21
US20230126862A1 (en) 2023-04-27
BR112022020881A2 (pt) 2022-11-29
JP7788730B2 (ja) 2025-12-19
IL297275A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
BR112022019206A2 (pt) Tratamento de infecções por coronavírus
BR112022017243A2 (pt) Lactoferrina para uso oral com ação antiviral
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
BR112015028879A2 (pt) derivados heterocíclicos
BR112013028813A2 (pt) derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
BR112012018170B8 (pt) agente antimicrobiano para redução, inibição ou tratamento do crescimento microbiano, infecções microbianas, doenças inflamatórias, doenças ou condições virais resultantes de ou associadas aos mesmos
BR112012012529A2 (pt) composto indol e seu uso farmacêutico
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
BR112016006589A2 (pt) composição, e composição de vacina
BR112012022509A2 (pt) procalcitonina para o diagnóstico de infecções bacterianas e orientação de tratamento antibiótico em pacientes com queixas não específicas.
MA35443B1 (fr) Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c
BR112022016117A2 (pt) Métodos para a prevenção ou o tratamento de ferimento ou falha em um órgão induzidos por vírus com dímero de il-22
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
BR112022020439A2 (pt) Aptâmeros para uso no tratamento de infecções de coronaviridae
BRPI0411429A (pt) tratamento de sintomas associados com vaginose bacteriana
ATE524488T1 (de) Lysobactinamide
BR112023019720A2 (pt) Uso de análogos de rifamicina em combinação com vancomicina, composição farmacêutica compreendendo esses compostos, método in vitro para prevenir ou inibir o crescimento de uma bactéria e kit
BR112023017987A2 (pt) Uso de uma combinação sinergística de colistina e fosfomicina, kit de partes, e, uso da associação farmacológica sinergística de colistina e fosfomicina
BRPI0913586A8 (pt) combinação, e, uso de uma combinação.
BR112021018222A2 (pt) Composição
CO2019009216A2 (es) Asociación de n-acetilcisteína y colistina para su uso en infecciones bacterianas
ZA202309185B (en) Aptamers for use in the treatment of coronaviridae infections
MX2023012943A (es) Compuesto antibacteriano.
BRPI0612431A2 (pt) composiÇÕes e mÉtodos para o tratamento da infecÇço hiv com cupredoxina e citocromo c

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]